AR070413A1 - Inhibidores macrociclicos de proteasa de serina - Google Patents

Inhibidores macrociclicos de proteasa de serina

Info

Publication number
AR070413A1
AR070413A1 ARP090100353A ARP090100353A AR070413A1 AR 070413 A1 AR070413 A1 AR 070413A1 AR P090100353 A ARP090100353 A AR P090100353A AR P090100353 A ARP090100353 A AR P090100353A AR 070413 A1 AR070413 A1 AR 070413A1
Authority
AR
Argentina
Prior art keywords
heterocyclyl
alkyl
aryl
alkynyl
cycloalkyl
Prior art date
Application number
ARP090100353A
Other languages
English (en)
Original Assignee
Idenix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Pharmaceuticals Inc filed Critical Idenix Pharmaceuticals Inc
Publication of AR070413A1 publication Critical patent/AR070413A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se provee compuestos inhibidores macrocíclicos de proteasa de serina, composiciones farmacéuticas que comprenden los compuestos y su proceso de preparacion. Además se proveen métodos para su uso en el tratamiento de una infeccion por HCV en un huésped que lo necesite. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un unico enantiomero, una mezcla racémica, o una mezcla de sus diastereomeros; o su sal, solvato o prodroga farmacéuticamente aceptable; en donde: R5 es -OH, -NR8R9, -NHS(O)2R8, -NHS(O)2NR8R9, -NHC(O)R8, -NHC(O)NR8R9, -C(O)R9, o -C(O)NR8R9, en donde cada R8 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, aIquiIo C1-6-cicloalquileno C3-7, -CH2NR8aR8b, -CH(R8c)NR8aR8b, -CHR8cCHR8dNR8aR8b, o -CH2CR8cR8dNR8aR8b, en donde: cada R8a, R8c, y R8d es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, arilo C6-4-alquileno C1-6, y cada R8b es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, heterociclilo, -S(O)kR11, -S(O)kNR11R12, -C(O)R11, -C(O)OR11, -C(O)NR11R12, o -C(=NR13)NR11R12; en donde cada R11, R12, y R13 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R11 y R12 junto con el átomo de N al cual están unidos forman heterociclilo; o R8a y R8b junto con el átomo de N al cual están unidos forman heterociclilo; y cada R9 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R8 y R9 junto con el átomo de N al cual están unidos forman heterociclilo; R6 es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, L es una ligadura, alquileno C1-6, cicloalquileno C3-7, alquenileno C2-6, alquinileno C2-6, X, o -(CR6aR6b)pX-; en donde p es un numero entero de 1, 2, o 3; R6a y R6b son cada uno independientemente hidrogeno, halo, ciano, hidroxilo, o alcoxi; y X es -O-, -C(O)-, -C(O)O-, -OC(O)O-, -C(O)NR14-, -NR14-, -NR14C(O)NR15-, -C(=NR14)NR15-, -NR14C(=NR15)NR16-, -S(O)k-, -S(O)kNR14-, -NR14S(O)kNR15-, -P(O)(OR14)-, o -OP(O)(OR14)-, donde cada R14, R15, y R16 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, y cada k es independientemente un numero entero de 1 o 2; Q1 es -O-, -N(R17)-, -C(R18R19)-, o -CR17(NR18R19)-; en donde: cada R17 y R18 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, y cada R19 es independientemente -R20, -C(O)R20, -C(O)OR20, -C(O)NR21R22, -C(=NR20)NR21R22, o -S(O)kR20; donde cada R20, R21, y R22 es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o R21 y R22 junto con el átomo de N al cual están unidos forman heterociclilo; o R18 y R19 junto con el átomo de C o N al cual están unidos forman cicloalquilo C3-7 o heterociclilo; Q2 es alquileno C3-9, alquenileno C3-9, o alquinileno C3-9, en donde cada uno contiene opcionalmente de uno a tres heteroátomos en la cadena, independientemente seleccionados de O, N, y S; y cada k es independientemente un numero entero de 1 o 2; en donde cada alquilo, alquileno, alquenilo, alquenileno, alquinilo, alquinileno, arilo, cicloalquilo, cicloalquileno, heterociclilo y heteroarilo es opcionalmente sustituido con uno o más grupos, cada uno independientemente seleccionado de ciano, halo, o nitro; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, cada uno opcionalmente sustituido con uno o más sustituyentes Q; o -C(O)Ra, -C(O)ORa, -C(O)NRbRc, -C(NRa)NRbRc, -ORa, -OC(O)Ra, -OC(O)ORa, -OC(O)NRbRc, -OC(=NRa)NRbRc, -OS(O)Ra, -OS(O)2Ra, -OS(O)NRbRc, -OS(O)2NRbRc, -NRbRc, -NRaC(O)Rb, -NRaC(O)ORb, -NRaC(O)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(O)Rb, -NRaS(O)2Rb, -NRaS(O)NRbRc, -NRaS(O)2NRbRc, -SRa, -S(O)Ra, o -S(O)2Ra; en donde cada Ra, Rb, Rc, y Rd es independientemente hidrogeno; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, cada uno opcionalmente sustituido con uno o más sustituyentes Q: o Rb y Rc junto con el átomo de N al cual están unidos forman heterociclilo, opcionalmente sustituido con uno o más sustituyentes Q; en donde cada Q es independientemente seleccionado del grupo que consiste en ciano, halo, o nitro; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o -C(O)Re, -C(O)ORe, -C(O)NRfRg, -C(NRe)NRfRg, -ORe, -OC(O)Re, -OC(O)ORe, -OC(O)NRfRg, -OC(=NRe)NRfRg, -OS(O)Re, -OS(O)2Re, -OS(O)NRfRg, -OS(O)2NRfRg, -NRfRg, -NReC(O)Rf, -NReC(O)ORf, - NReC(O)NRfRg, -NReC(=NRh)NRfRg, -NReS(O)Rf, -NReS(O)2Rf, -NReS(O)NRfRg, -NReS(O)2NRfRg, -SRe, -S(O)Re, o -S(O)2Re; en donde cada Re, Rf, Rg, y Rh es independientemente hidrogeno; alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo C6-14, heteroarilo, o heterociclilo, o Rf y Rg junto con el átomo de N al cual están unidos forman heterociclilo.
ARP090100353A 2008-02-04 2009-02-03 Inhibidores macrociclicos de proteasa de serina AR070413A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2608608P 2008-02-04 2008-02-04
US8386708P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
AR070413A1 true AR070413A1 (es) 2010-04-07

Family

ID=40568607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100353A AR070413A1 (es) 2008-02-04 2009-02-03 Inhibidores macrociclicos de proteasa de serina

Country Status (22)

Country Link
US (2) US8003659B2 (es)
EP (1) EP2250174B1 (es)
JP (1) JP5574982B2 (es)
KR (1) KR20100118991A (es)
CN (1) CN101977915B (es)
AR (1) AR070413A1 (es)
AU (1) AU2009210789B2 (es)
BR (1) BRPI0908021A2 (es)
CA (1) CA2712971A1 (es)
CO (1) CO6501153A2 (es)
CR (1) CR11618A (es)
EC (1) ECSP10010413A (es)
ES (1) ES2437147T3 (es)
HK (1) HK1144198A1 (es)
IL (1) IL207333A0 (es)
MX (1) MX2010008523A (es)
NI (1) NI201000136A (es)
NZ (1) NZ587133A (es)
RU (1) RU2490272C2 (es)
TW (1) TW200936131A (es)
WO (1) WO2009099596A2 (es)
ZA (1) ZA201005318B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
AR066528A1 (es) 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
CN102046622A (zh) 2008-04-15 2011-05-04 因特蒙公司 丙型肝炎病毒复制的新颖大环抑制剂
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EA019965B1 (ru) 2008-09-17 2014-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
US8309737B2 (en) 2009-02-03 2012-11-13 Idenix Pharmaceuticals, Inc. Phosphinate ruthenium complexes
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010107965A1 (en) * 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
DK2451438T3 (da) 2009-07-07 2014-03-10 Boehringer Ingelheim Int Farmaceutisk sammensætning til en hepatitis C-virus-roteaseinhibitor
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012009503A1 (en) * 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ES2563479T3 (es) 2012-01-11 2016-03-15 Abbvie Inc. Procedimientos para elaborar inhibidores de proteasa de VHC
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
AU2014233390B2 (en) 2013-03-15 2018-03-01 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis C virus
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079912C (en) 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
EE04023B1 (et) 1996-10-18 2003-04-15 Vertex Pharmaceuticals Incorporated Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
HUP0100100A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CN1441806A (zh) 2000-04-05 2003-09-10 先灵公司 包含n-环p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
AU2001253621A1 (en) 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2001277967A1 (en) 2000-07-21 2002-02-05 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
CA2410682A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CZ303213B6 (cs) 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
IL155842A0 (en) 2000-12-12 2003-12-23 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US20040110126A1 (en) * 2001-03-08 2004-06-10 George Kukolj Hcv polymerase inhibitor assay
US6841566B2 (en) * 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370400A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2361011T3 (es) 2002-05-20 2011-06-13 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c.
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050069522A1 (en) * 2002-08-12 2005-03-31 Richard Colonno Combination pharmaceutical agents as inhibitors of HCV replication
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
JP4550824B2 (ja) * 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎抑制化合物
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
KR20060008877A (ko) 2003-04-10 2006-01-27 베링거 인겔하임 인터내셔날 게엠베하 루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법
ES2381548T3 (es) 2003-04-11 2012-05-29 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
PL1615613T3 (pl) * 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
PE20050204A1 (es) * 2003-05-21 2005-05-04 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
CA2536182C (en) * 2003-09-22 2012-07-24 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
RU2006115558A (ru) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
DE10348044A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN1902216A (zh) * 2003-11-20 2007-01-24 先灵公司 丙肝病毒ns3蛋白酶的去肽化抑制剂
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
EP1687021B1 (en) * 2003-11-20 2013-11-06 Boehringer Ingelheim International GmbH Method of removing transition metals, especially from metathesis reaction products
US7109344B2 (en) * 2003-12-04 2006-09-19 Boehringer Ingelheim International Gmbh Ruthenium catalyst
ES2320776T3 (es) * 2003-12-08 2009-05-28 Boehringer Ingelheim International Gmbh Eliminacion de subproductos de rutenio por tratamiento con fluidos supercriticos.
DE602004026629D1 (de) * 2003-12-15 2010-05-27 Japan Tobacco Inc Cyclopropanderivate und ihre pharmazeutische verwendung
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP1711514B1 (en) 2004-01-28 2008-12-03 Boehringer Ingelheim International GmbH Method of removing transition metals from reaction solutions comprising transition metal byproducts
EP1713822B1 (en) * 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitors
US7173057B2 (en) 2004-02-27 2007-02-06 Schering Corporation Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
JP2007525510A (ja) 2004-02-27 2007-09-06 シェーリング コーポレイション C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての化合物
US20050209135A1 (en) * 2004-03-15 2005-09-22 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
WO2006000085A1 (en) 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
ES2468441T3 (es) 2004-07-16 2014-06-16 Gilead Sciences, Inc. Compuestos heteroc�clicos antivirales que tienen grupos fosfonato
ATE512971T1 (de) * 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CN101068828A (zh) 2004-08-27 2007-11-07 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
JP2008513452A (ja) * 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 超臨界流体中の閉環複分解方法
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
DE102005002336A1 (de) * 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006130687A2 (en) 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20070237818A1 (en) 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
CA2615921C (en) 2005-07-20 2011-09-13 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新規大環状阻害剤
WO2007014925A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007017144A2 (en) * 2005-07-29 2007-02-15 Medivir Ab Macrocylic inhibitors of hepatitis c virus
PE20070210A1 (es) 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0614696A2 (pt) 2005-07-29 2011-04-12 Tibotec Pharm Ltd inibidores macrocìclicos de vìrus da hepatite c
EP2402331A1 (en) 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1934243B1 (en) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Ring-closing metathesis process for the preparation of macrocyclic peptides
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101401438B (zh) * 2006-03-15 2013-03-27 英国电讯有限公司 视频编码
CN101421292A (zh) 2006-04-11 2009-04-29 诺瓦提斯公司 Hcv抑制剂
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
US8268776B2 (en) * 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US20080187516A1 (en) 2006-06-06 2008-08-07 Ying Sun Acyclic oximyl hepatitis c protease inhibitors
US20070281884A1 (en) 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
TWI454264B (zh) 2006-06-26 2014-10-01 Enanta Pharm Inc 喹啉基巨環c型肝炎病毒絲胺酸蛋白酶抑制劑
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
US7935670B2 (en) * 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007272839B2 (en) * 2006-07-13 2012-05-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
DE112007002231A5 (de) * 2006-07-21 2009-06-25 Schaeffler Kg Verfahren zum Erkennen eines Laschentyps bei einer Kette
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20090035271A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
TW200827364A (en) * 2006-11-02 2008-07-01 Taigen Biotechnology Co Ltd HCV protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2684086C (en) 2007-04-24 2014-05-27 F. Hoffmann-La Roche Ag Process for hcv protease inhibitor intermediate
US20080274082A1 (en) 2007-04-26 2008-11-06 Yonghua Gai Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor
US7910587B2 (en) 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
US20080286233A1 (en) 2007-04-26 2008-11-20 Ying Sun Piperizinyl macrocyclic hepatitis c serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
US20080274080A1 (en) 2007-04-26 2008-11-06 Yat Sun Or Aza-peptide macrocyclic hepatitis c serine protease inhibitors
US20080317712A1 (en) 2007-04-26 2008-12-25 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors
US20080287449A1 (en) 2007-04-26 2008-11-20 Deqiang Niu Aza-tripeptide hepatitis c serine protease inhibitors
US20080292587A1 (en) 2007-04-26 2008-11-27 Ying Sun Oximyl dipeptide hepatitis c protease inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EP2162432A2 (en) * 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antiviral compounds
US8178491B2 (en) * 2007-06-29 2012-05-15 Gilead Sciences, Inc. Antiviral compounds
WO2009014730A1 (en) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP2010540549A (ja) * 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ,インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8962551B2 (en) * 2007-12-05 2015-02-24 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
EP2224920A4 (en) * 2007-12-06 2012-05-09 Enanta Pharm Inc PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS

Also Published As

Publication number Publication date
US8093379B2 (en) 2012-01-10
NI201000136A (es) 2011-03-23
US8003659B2 (en) 2011-08-23
ECSP10010413A (es) 2010-11-30
CR11618A (es) 2011-01-31
EP2250174A2 (en) 2010-11-17
US20090202480A1 (en) 2009-08-13
MX2010008523A (es) 2010-08-31
RU2010136973A (ru) 2012-03-20
WO2009099596A3 (en) 2009-12-03
IL207333A0 (en) 2010-12-30
KR20100118991A (ko) 2010-11-08
NZ587133A (en) 2012-10-26
CN101977915B (zh) 2014-08-13
ZA201005318B (en) 2011-10-26
US20100016578A1 (en) 2010-01-21
RU2490272C2 (ru) 2013-08-20
AU2009210789A1 (en) 2009-08-13
JP5574982B2 (ja) 2014-08-20
CN101977915A (zh) 2011-02-16
WO2009099596A2 (en) 2009-08-13
AU2009210789B2 (en) 2014-01-30
EP2250174B1 (en) 2013-08-28
WO2009099596A4 (en) 2010-02-04
HK1144198A1 (en) 2011-02-02
TW200936131A (en) 2009-09-01
ES2437147T3 (es) 2014-01-09
JP2011520772A (ja) 2011-07-21
BRPI0908021A2 (pt) 2015-07-21
CA2712971A1 (en) 2009-08-13
CO6501153A2 (es) 2012-08-15

Similar Documents

Publication Publication Date Title
AR070413A1 (es) Inhibidores macrociclicos de proteasa de serina
AR076251A1 (es) Inhibidores de la proteasa serina macrociclica
AR077712A1 (es) Inhibidores de serina proteasa macrociclica
AR113964A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
CO5700736A2 (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
CO5660261A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de estos y usos de estos
NZ612159A (en) Macrocyclic inhibitors of flaviviridae viruses
AR074543A1 (es) Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
PE20090994A1 (es) Derivados de azaindol 2,3-sustituidos como agentes antivirales
AR105340A2 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
AR076267A1 (es) Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CR8756A (es) Derivados de acido carboxilico bencimidazolona
AR040335A1 (es) Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR063637A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR080945A1 (es) Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
AR079231A1 (es) Derivados de imidazoquinolina
ECSP12011684A (es) Inhibidores de los virus flaviviridae.

Legal Events

Date Code Title Description
FB Suspension of granting procedure